Business Wire

SmileMate Virtual Consultation – Free Until 31st May

Share

Dental Monitoring announced last week the launch of a simplified version of SmileMate Virtual Consultation - its tele dentistry solution to allow dental professionals to assess their new patient enquiries remotely and in a HIPAA compliant manner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200324005658/en/

Photo: SmileMate by DentalMind

Photo: SmileMate by DentalMind

Given the scale of the pandemic, and the increasing containment measures taken by governments worldwide, tele dentistry such as SmileMate Virtual Consultation has emerged as a solution to help assess patients remotely in these unprecedented times - initiating a first consultation from home and preventing the spread of COVID-19.

Standing alongside all dental professionals, Dental Monitoring has now decided to provide until the end of May 2020, free access for SmileMate Virtual Consultation to all individual dentists and orthodontists worldwide.

SmileMate Virtual Consultation is a “light” version of SmileMate, simpler and more immediate to implement for these times - enabling rapid on-boarding and roll-out. It has been developed to allow practices to remotely assess their new patients directly through their website.

CEO and Co-founder of Dental Monitoring, Philippe Salah, explained: “Allowing free access to our solution until the end of May is our duty as global citizens. It is important that we help dental professionals find solutions so they can keep providing their expert care, even during the pandemic.”

On the accelerated development of SmileMate Virtual Consultation, CEO and Founder of SmileMate, Nick Duncan said: “I think I speak for the entire dental industry when I say that our sole focus at this time is to do whatever we can to help clinics get through the current period of uncertainty. We've worked hard to develop a new version of our technology that is easier to implement for both patients and individual clinics. As a partner of dental professionals, making it free for all independent dentists and orthodontists was the right thing to do.”

Dental Monitoring is working with dental professionals, to improve its solutions and help patients access dental care anytime, anywhere.

About SmileMate Virtual Consultation, remote assessment of new patients.
All new patient calls can be pre-qualified remotely using the SmileMate Virtual Consultation assessment tool directly through the doctor’s practice website. The process is simple:

Step 1- The doctor simply installs a widget on its practice website. The new patient clicks on the widget, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an App or use a ScanBox and cheek retractors)

Step 2- A comprehensive customized report is automatically generated by our AI engine and sent to the doctor

Step 3- The doctor qualifies the patient’s needs on their SmileMate portal

Step 4- The doctor reviews and personalizes the report before sharing with the patient together with their treatment options and a booking link if an appointment is required.

To implement SmileMate Virtual Consultation, please visit: https://dental-monitoring.com/maintain-patient-care/

After May 31st, 2020, and until the end of the pandemic,SmileMate Virtual Consultation will be available at a reduced 50% cost: US$150/month.

About Fast-Track Accelerated On-Boarding
SmileMate Virtual Consultation is ready for use in minutes after doctors and their teams have performed our free fast-track accelerated onboarding - a new simplified and streamlined implementation process, which is done 100% remotely through webinars and individual support by our customer support team.

To book a time slot for our next training session, please visit: https://dental-monitoring.com/maintain-patient-care/

About Dental Monitoring (www.dental-monitoring.com)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company addressing the dental market. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the dental professionals, and after treatment to ensure the stability of the treatment outcome. The company operates in Europe, the United States and Asia-Pacific. It employs around 250 employees across its five offices located in Paris, Austin, London, Hong Kong and Sydney. SmileMate is a subsidiary of Dental Monitoring (https://www.smilemate.com/).

Contact information

Press Contact: Charlotte Garzino: c.garzino@dental-monitoring.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mobidiag Offers Complete Diagnostic Solution for the Detection of Novel Coronavirus Infections with Both PCR and Antibody Tests2.6.2020 06:00:00 CESTPress release

Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address infectious diseases, antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received CE-IVD markings for its https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Novodiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Novodiag%26%23174%3B+COVID-19&index=1&md5=a6f8720fcb65487af8166329d2b56957 Novodiag® COVID-19 and https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmobidiag.com%2Fproducts%2Fcoronavirus-1%2F%23Amplidiag-COVID-19&esheet=52228608&newsitemid=20200601005614&lan=en-US&anchor=Amplidiag%26%23174%3B+COVID-19&index=2&md5=3dc50805e09ec072bce2a6e5aa75368a Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). These tests complement the Company’s al

Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CESTPress release

Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a

New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CESTPress release

The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005162/en/ Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CESTPress release

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005257/en/ Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is

Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CESTPress release

Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest

Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CESTPress release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005142/en/ Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the